Unlike CC-885, which triggers the degradation of additional CRBN substrates, CC-90009 seems to have little to no effect on the rest of the proteome and CC-90009 is the first eRF3a degrader to enter clinical trials in patients with relapsed or refractory AML (24,26). This evidence concerns the gene CRBN and acute myeloid leukemia.